Acute Lymphocytic / Lymphoblastic Leukemia Market - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Acute Lymphocytic / Lymphoblastic Leukemia Market

Description:

The acute lymphoblastic leukemia therapeutics market is segmented based on the existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials). – PowerPoint PPT presentation

Number of Views:233

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Acute Lymphocytic / Lymphoblastic Leukemia Market


1
MarketsandMarkets Presents
Acute Lymphocytic/Lymphoblastic Leukemia
Therapeutics Market
http//www.marketsandmarkets.com/Market-Reports/ac
ute-lymphocytic-leukemia-therapeutics-market-518.h
tml
2
The acute lymphoblastic leukemia therapeutics
market is segmented based on the existing
regimens and drugs, pipeline drugs, and
geography. The existing regimes and drugs market
currently includes three regimens (Hyper-CVAD,
Linker, and CALGB 8811) and three monotherapy
drugs (Oncaspar, Clolar, and Arranon). In
addition, three drugs, namely, Graspa (ERYtech
Pharma), Marqibo (Talon Therapeutics), and
Inotuzumab Ozogamicin (Pfizer, Inc.) are in the
pipeline (Phase III clinical trials). The acute
market is valued at an estimated 2,777.2 million
in 2013 and is expected to reach 3,780.3 million
by 2020, at a CAGR of 4.0 from 2015 to
2020. Browse gtgt http//www.marketsandmarkets.com/M
arket-Reports/acute-lymphocytic-leukemia-therapeut
ics-market-518.html
                   
                    

3

Acute Lymphocytic/Lymphoblastic Leukemia Market
in G8 Countries, By Existing Regimen/Drugs
(Million)
Source MarketsandMarkets Analysis
http//www.marketsandmarkets.com/Market-Reports/ac
ute-lymphocytic-leukemia-therapeutics-market-518.h
tml
4
Presently, the market is driven by factors such
as the increasing incidence rate of ALL cases,
development of innovative therapies such as
multi-drug regimens, and continuous efforts of
pharmaceutical companies to offer
superior-quality drugs. Such improved regimens
and drugs have shown significant results in the
overall survival rate. The overall growth of the
acute lymphocytic leukemia therapeutics market is
largely challenged by the patent expiration of
existing drugs. Arranon (nelarabine), a
monotherapy drug, lost its patent in February
2013, whereas, Clolar (clofarabine) is due for
patent expiration in 2018. Some of the major
players in this market include ERYtech Pharma
(France), Talon Therapeutic, Inc. (U.S.),
GlaxoSmithKline plc (U.K.), Sigma-Tau
Pharmaceuticals, Inc. (U.S.), Pfizer, Inc.
(U.S.), and Genzyme Corporation (U.S.). .
http//www.marketsandmarkets.com/Market-Reports/a
cute-lymphocytic-leukemia-therapeutics-market-518.
html
5
The market primarily covers regimens and drugs
(patented, off-patent, and pipeline). The growing
acute lymphocytic leukemia population is an
impetus for the growth of the market. This market
is expected to grow at a CAGR of 4.0 from 2015
to 2020. In 2012, the overall ALL therapeutics
market was dominated by Linker regimen,
Hyper-CVAD regimen, and Nucleoside metabolic
inhibitors treatments. However, by 2020, the
overall share of these drugs and regimens will be
largely impacted by the launch of Graspa
(ERYtechPharma), an innovative form of
L-Asparaginase, followed by Marqibo (Talon
Therapeutics) and Inotuzumab Ozogamicin (Pfizer,
Inc.). In contrast to the growth of the market,
the cost of the therapies is majorly restraining
the acute lymphocytic leukemia therapeutics
market. In addition, patent expirations of some
of the existing drugs in the market are also
expected to limit the market growth during 2013
to 2020.
http//www.marketsandmarkets.com/Market-Reports/ac
ute-lymphocytic-leukemia-therapeutics-market-518.h
tml
6
Contact Us
Mr. RohanNorth - Dominion Plaza, 17304 Preston
Road, Suite 800, Dallas, TX 75252Tel
1-888-6006-441Email sales_at_marketsandmarkets.com
 MarketsandMarkets Bloghttp//twitter.com/market
smarkets
http//www.linkedin.com/company/marketsandmarkets
http//www.marketsandmarkets.com/Market-Reports/ac
ute-lymphocytic-leukemia-therapeutics-market-518.h
tml
7
About MarketsandMarkets
MarketsandMarkets is a global market research and
consulting company based in the U.S. We publish
strategically analyzed market research reports
and serve as a business intelligence partner to
Fortune 500 companies across the
world. MarketsandMarkets also provides
multi-client reports, company profiles,
databases, and custom research services. They
cover thirteen industry verticals, including
advanced materials, automotives and
transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy
and power, food and beverages, industrial
automation, medical devices, pharmaceuticals,
semiconductor and electronics, and
telecommunications and IT. We at
MarketsandMarkets are inspired to help our
clients grow by providing apt business insight
with our huge market intelligence repository.
http//www.marketsandmarkets.com/Market-Reports/ac
ute-lymphocytic-leukemia-therapeutics-market-518.h
tml
About PowerShow.com